StemCell Therapy

Clival chordoma (CC) is a rare neoplasm that arises from remnants of the embryonic notochord. Common sites of chordoma development are the sacrococcygeal area and the skull base. Intracranial chordomas usually arise from the region of the clivus. Diplopia is a common complaint but isolated optic nerve compression is rare; among intracranial neoplasms, chordomas were found in less than 0.7% of cases. We describe a case of visual loss due to unilateral compressive optic neuropathy as the presenting manifestation of this uncommon intracranial tumor.

A 26-year-old man presented complaining of progressive visual loss in the right eye (OD) for the past eight months. He denied headache, diplopia, or any other neurologic symptoms and felt otherwise well. His past medical history was non-contributory and he was taking no medications. Best-corrected visual acuity (BCVA) was 20/200 OD and 20/20 in the left eye (OS). Extraocular motility was full. External exam was normal and there was no proptosis or ptosis. Pupils were isocoric with a right relative afferent pupillary defect (RAPD). Intraocular pressure measurements and anterior segment examination were within normal limits in both eyes (OU). Fundus examination (Figure 1) revealed optic nerve pallor OD and a normal optic disc OS.

The standard computerized visual field (Figure 2) showed a diffuse defect OD and a superior mild fascicular defect OS. Magnetic resonance imaging (MRI) of the brain showed a large intracranial mass with radiologic features of CC (Figure 3), with the upward displacement of the chiasm and asymmetric involvement of optic nerves (figure 4). The patient underwent subtotal neurosurgical resection and pathology was consistent with a chordoma (Figure 5) but there was no improvement in visual acuity or visual field.

CC is a rare neoplasm with an incidence rate of less than 0.1 per 100.000 per year [1]. CCs arise from remnants of the embryonic notochord [2] and show both epithelial and mesenchymal differentiation. Common sites of chordoma development are the sacrococcygeal area in 50-60% of cases and the skull base (spheno-occipital area) in 25-35% of the cases. Uncommonly, it may develop from cervical, thoracic, or lumbar vertebrae [3].

Histologically chordomas show a typical pattern of lobules separated by fibrous bands. Each lobule displays vacuolated, atypical neoplastic cells within a myxoid stroma [4]. Age at presentation is around the fifth or sixth decades for the sacrococcygeal type and even earlier for skull-base chordomas [3].

In several large reviews of patients with intracranial neoplasms, chordomas were found in 0.1-0.7% of patients [5]. Intracranial chordomas usually arise from the region of the clivus and account, as previously reported, for about one-third of all cases [3]. Although the tumor rarely metastasizes, advanced secondary lesions may affect the lungs, bone, liver soft tissues, lymph nodes, and skin [6].When arising from the clivus, common symptoms are headache, facial numbness, nasal discharge, dysphagia, and cranial nerve palsy. Diplopia is a common complaint since the most common cranial nerve to be compressed is the sixth cranial nerve with unilateral or bilateral abducens deficit. Third and fourth nerve palsies are also possible as well as complete unilateral ophthalmoplegia from multiple cranial nerve involvement.

Volpe and coworkersreviewed the neuro-ophthalmologic findings in chordomas and chondrosarcomas of the skull base [5]. In the group of 48 patients with chordoma, decreased visual acuity was present in only four patients (8%) but in only two cases (4%) was visual loss an isolated finding.The pattern of the visual field loss differed in each patient, with some displaying a central scotoma, altitudinal defects, junctional scotoma, or bi-temporal hemianopsia. In a series of 12 patients, Harbour and coworkers found that visual loss was present in only three patients (25%), but none of them complained of visual loss as the presenting symptom [7]. In another case series of 63 patients affected by intracranial chordoma, Bagan et al. found 39 patients (62%) with isolated ophthalmic manifestations [8].Visual loss was present in only 10 patients (16%) and among those patients who initially had only one symptom, only three of them (4.7%) complained of isolated visual loss.

Although isolated and progressive unilateral visual loss from compression of the anterior visual pathway is an uncommon finding in CC, clinicians should be aware of this presentation. Neuroimaging typically demonstrates the compressive lesion and the origin at the clivus consistent with CC. Gross total resection is the best treatment.

Read more here:
Unilateral Compressive Optic Neuropathy As the Presenting Manifestation of Clival Chordoma: A Case Report - Cureus

Trigeminal neuropathies (TNp) are a group of well-characterized disorders that involve damage to or infiltration of the trigeminal nerve. The underlying etiology of trigeminal neuropathy can be traumatic, inflammatory, autoimmune, paraneoplastic, malignant, and very rarely infectious. We present a case of trigeminal neuropathy due to local malignant invasion of the mandibular nerve with mandibular nerve enhancement at the foramen ovale and foramen rotundum. In the process, we review various etiologies of trigeminal neuropathy associated with trigeminal nerve involvement at the foramina. We emphasize the importance of a comprehensive evaluation in patients with trigeminal neuropathy, which includes searching for perineural spread or invasion by a local head and neck malignancy, as well as ruling out an inflammatory or autoimmune etiology. Our case also demonstrates that a higher field strength magnet can reveal pathology unseen with a lower field strength magnet.

The trigeminal nerve, cranial nerve V, is the largest of the 12 cranial nerves and has mixed sensory and motor functions. Its origin is in the brainstem and includes three sensory nuclei (mesencephalic, principal sensory, and spinal nucleus of the trigeminal nerve) and one motor nucleus (motor nucleus of the trigeminal nerve). Sensory information travels via afferent neurons from the face to the trigeminal ganglion and distributes via the various sensory trigeminal nuclei. Sensory information, such as pain and temperature, is then relayed to the contralateral thalamus and eventually synapses in the postcentral gyrus. Motor information travels via efferent neurons from the motor nucleus directly to its targets: masseters, temporalis, and pterygoid muscles [1,2].

The trigeminal nerve divides into three branches at the Gasserian ganglion in Meckels cave [3]. The three branches consist of the ophthalmic nerve (V1), the maxillary nerve (V2), and the mandibular nerve (V3). The ophthalmic nerve (V1) travels through the cavernous sinus, exits the base of the skull, and enters the orbit via the superior orbital fissure. The maxillary nerve (V2) accompanies the ophthalmic nerve in the cavernous sinus as it makes its way to the pterygopalatine fossa by exiting the skull base via the foramen rotundum. At the pterygopalatine fossa, the maxillary nerve splits into many branches. A trigeminal nerve deficit (V1 and V2) and a sixth nerve palsy localize a lesion to the cavernous sinus. The mandibular nerve (V3) does not traverse the cavernous sinus but runs along and eventually exits the base of the skull via the foramen ovale into the masticator space [4].

The ophthalmic and maxillary nerves are sensory branches of the trigeminal nerve. The ophthalmic division branches into the frontal, lacrimal, nasociliary, tentorial, and dural nerves. These nerves provide sensory innervation to the cutaneous surfaces of the upper eyelids, forehead, and sides of the nose. The nasociliary nerve specifically innervates the tip and the sides of the nose, and its involvement in herpes zoster ophthalmicus is known as Hutchinsons sign. The ophthalmic branches also innervate the mucosa of the frontal sinus, lacrimal glands, cornea, conjunctiva, ciliary body, and dura mater [5]. Damage to some of these branches, more specifically to the parasympathetic efferent nerves of the lacrimal glands, can manifest as dry eyes in Sjogrens syndrome. The maxillary division of the trigeminal nerve branches into the infraorbital, zygomatic, greater palatine, lesser palatine, posterior superior alveolar, and meningeal nerves. These nerves provide sensory innervation to the region below the orbit and above the mouth, the maxillary teeth, and the maxillary sinus.

The mandibular division of the trigeminal nerve is unique in that it branches into both sensory and motor nerves. Sensory nerves include meningeal, lingual, auriculotemporal, inferior alveolar, buccal, and mental nerves. A mental neuropathy with numbness of the chin is a sinister sign of local malignant invasion. These nerves provide sensory information to the region below the mouth, the mandibular teeth, and the anterior two-thirds of the tongue. The motor nerves include the masseteric, deep temporal, medial pterygoid, lateral pterygoid, and mylohyoid branches. A motor nerve root supplies the tensor veli palatini, a lesion of which causes palatal myoclonus. Another motor twig goes to the tensor tympani, and injury here leads to hyperacusis [2,5]. It should also be emphasized that the mandibular branches, with the ophthalmic branches, supply the dura mater of the anterior and middle cranial fossa.

Neoplastic, autoimmune, paraneoplastic, and autoimmune processes can damage the trigeminal nerve, leading to trigeminal neuropathy (TNp) [6,7]. The characteristic findings of TNp include facial numbness and weakness of the muscles of mastication. TNp is different from trigeminal neuralgia (TN), which is characterized by episodes of sudden, very brief, severe, sharp, shooting facial pain. The initial presentation of TNp can include pain; however, with disease progression, facial numbness and masticatory muscle weakness may predominate [8]. As TNp may be the initial presentation, malignancies of the head and neck should always be in the differential diagnosis, and a high-resolution magnetic resonance imaging (MRI) of the brain and skull base with and without gadolinium enhancement is paramount [9].

We present the case of a relatively healthy 80-year-old female who presented to the clinic with a several month history of recurrent sharp, shooting left midfacial pain. The pain was associated with tingling in the left half of the face and loss of taste. With initial symptom presentation, the patient went to the emergency department and was diagnosed with Bells palsy and was given gabapentin for the pain. At her follow-up at the neurology clinic, she presented with unimproved symptoms in addition to newly developed left lower facial weakness and occasional chewing difficulty. She denied hyperacusis.Twenty years ago, she had presented with a left midface nodule, which was excised and diagnosed as a basal cell carcinoma. She has not had a recurrence since.

Her past medical history is significant for hypertension, for which she takes lisinopril 10 mg once daily. The patient denied any significant family history. She has never smoked, does not consume alcohol, and denies using any illicit or recreational drugs. Constitutional symptoms including weight loss, fever, and malaise were not reported.

Vital signs revealed a blood pressure (BP) of 170/91 mmHg with a pulse of 81 beats per minute and oxygen saturation of 97%. The patients height was 5 feet and 8 inches with a weight of 185 pounds and a body mass index of 28.1 kg/m2. Physical examination showed a well-nourished individualwhowas alert, relaxed, and cooperative. The patient was oriented to person, place, situation, and time. Gait was steady with a normal base, arm swing, and turning. Heel- and toe-walking was normal with an absent Romberg sign. Speech was of normal tone, volume, and prosody.

Cranial nerve examination revealed normal extraocular motion with symmetric pupils and preserved accommodation, and visual fields were full to confrontation. There was a striking decrease insensationto touch and pinprick over the left V2 and V3 distribution. The corneal reflex was brisk bilaterally. No masseter or temporal muscle atrophy was noted bilaterally. Left lower facial weakness was noted with depressed nasolabial fold, inability to blow the left cheek,andconspicuous sagging of the left lower face. Hearing was intact to finger rub bilaterally. The gag reflex was preserved bilaterally with a tongue that protruded to the midline. The trapezii and sternocleidomastoids were well developed and symmetric, and she executed shoulder shrug and head-turning with adequate power.

Motor examination showed good muscle bulk and tone. No pronator drift or spastic catch of the arms was noted, and the legs were of normal tone. Strength was graded at 5/5 with the Medical Research Council (MRC) rating scale in the upper and lower extremities bilaterally. Sensation to vibration, position, light touch, and pinprick was normal in the fingers and toes. Deep tendon reflexes (biceps, triceps, brachioradialis, patellar, and Achilles) were lively and bilaterally symmetric. Babinski sign was absent bilaterally. Finger-to-nose and heel-to-shin motions were normal bilaterally. An initial 1.5-Tesla MRI of the brain with and without contrast revealed an asymmetrical enhancement of the left mandibular branch of the trigeminal nerve as it extended through the foramen ovale(Figure 1).

A second 3-Tesla high-resolution MRI of the brain and skull base with and without contrast showed far more detail than the lower 1.5-Tesla MRI with abnormal enhancement of the left nasolabial fold and perineural tumor spread along the left infraorbital nerve to the left pterygopalatine fossa (Figure 2).

A lumbar puncture was performed; cerebrospinal fluid (CSF) was negative for malignant cells by flow cytometry, and the CSF findings are summarized in Table 1.

Isoelectric focusing (IEF) and immunoblotting were used to perform oligoclonal banding testing. One paired band and zero nucleated cells were found in both the CSF and serum, which indicates an inflammatory process outside the central nervous system. Zero oligoclonal bands were found in the CSF, which rules out an ongoing central nervous system inflammatory process.

A paraneoplastic panel including anti-acetylcholine receptor ganglionic neuronal antibodies, anti-amphiphysin antibodies, anti-glial nuclear antibody type 1, anti-neuronal nuclear antibody type 2, anti-neuronal nuclear antibody type 3, collapsing response-mediator protein-5 (CRMP-5) immunoglobulin G, neuronal voltage-gated potassium channel antibodies, calcium channel antibody P/Q-type, and Purkinje cell cytoplasmic antibodies were negative.A referral to the ear-nose-throat (ENT) specialist revealed no cervical adenopathy or neck masses. A computed tomography (CT) scan of the chest, abdomen, and pelvis did not reveal evidence of malignancy. The patient refused a facial nerve biopsy of a facial nerve twig of the parotid gland and other invasive procedures including a skin biopsy over the nasolabial fold. It was determined that the likely source of the malignant perineural spread along the skull base foramina (foramen rotundum and ovale) was dormant basal cell carcinoma cells. The patient received proton beam radiation therapy to the involved sites, including the maxillary region of the face, the involved sinuses, and the skull base.

Neoplastic involvement of the trigeminal nerve can cause TNp and can pathologically be attributed to nerve compression, perineural spread (PNS), and/or perineural invasion (PNI). Metastasis from breast or lung cancer to the Gasserian ganglion is rare, as is leptomeningeal metastasis, which is usually lymphomatous [8,10]. Carcinomatous leptomeningitis can affect other cranial nerves and can rarely present with an isolated TN and/or TNp [11].Most primary tumors of the trigeminal nerve are due to a schwannoma and rarely are due to meningioma, lipoma, or epidermoid tumor [12].

The peripheral and cranial nerves harbor three layers of connective tissue across their diameter: endoneurium, perineurium, and epineurium. The perineural space is located between the nerve axon and the perineural layer. This potential space can allow for tumor spread and growth. There are two types of perineural tumor growth: perineural invasion (PNI) and perineural spread (PNS). PNI is defined by malignant cells invading the perineural space and is a histological diagnosis. PNS is a radiological diagnosis of malignant spread along the nerve and is identified by enhancement detected by high-resolution MRI. During the initial stages of the disease, only PNI may be present. As disease progression occurs, PNI can become PNS, which is clinically more aggressive [13,14]. A patient with numbness to the territory innervated by the mental branch of the mandibular nerve should always raise a red flag. The mental branch is purely sensory in function and provides cutaneous innervation to the lower lip and chin. This characteristic numbness is aptly named the numb-chin syndrome. Malignant mental neuropathy can indicate the presence and/or recurrence of a malignant tumor [15]. Facial numbness that spreadsand radiates into the tongue, roof of the mouth, and inside the cheeks should raise a high index of suspicion for an inflammatory or malignant invasion of the trigeminal nerve.

Hence, perineural tumor spread of carcinoma may be seen along the maxillary and mandibular division of the trigeminal nerve. Nerve enhancement is one of the radiological findings in perineural tumor spread and can serve as a dependable sign. High-resolution MRI is the imaging modality of choice due to its ability to demonstrate soft tissue in high detail. MRI enhancement of the mandibular nerve in asymptomatic patients is very uncommon and was only seen in 3% of patient cases without symptoms of TNp. Therefore, when symptomatic maxillary or mandibular nerve enhancement is discovered on MRI, a high index of suspicion for an underlying disease process should be raised [16,17].

Perineural spread of head and neck cancers is a well-described phenomenon. At the cellular level, neural secretion of glial-derived neurotrophic factor (GDNF) may allow perineural spread. GDNF phosphorylates the rearranged during transfection (RET) tyrosine kinase receptor that triggers downstream signaling pathways that allow malignant cell migration [18]. Adenoid cystic carcinoma and squamous cell carcinoma are the most common malignancies that can spread perineurally [3]. Although not the most common, basal cell carcinoma has been described in the literature. However, very few cases exist where the only clinical manifestation of basal cell carcinoma recurrence is trigeminal neuropathy [19].

Additional etiologies of TNp include inflammatory, autoimmune, paraneoplastic, and infectious disorders. Inflammatory/autoimmune etiologies include sarcoidosis, Lymes disease, Sjogrens syndrome, and systemic lupus erythematosus [8]. Malignancies that can cause paraneoplastic syndrome include, but are not limited to, small cell lung cancer, breast cancer, ovarian cancer, and pancreatic cancer. TNp can be one of the first clinical manifestations of a paraneoplastic syndrome [20]. Infectious causes include leprosy, herpes simplex virus, varicella-zoster virus, actinomycosis, and aspergillus [8].

In conclusion, the diagnosis of trigeminal neuropathy should evoke a specific set of differential diagnoses. Since trigeminal neuropathy can be one of the first and only manifestations of a head and neck tumor, local malignant perineural invasion should be seriously considered. A high-resolution MRI of the skull base with and without gadolinium contrast enhancement should be ordered as our case demonstrates that a higher magnetic field strength can highlight pathology not seen with lower magnetic field strength MRI.

See original here:
A Case of Secondary Trigeminal Neuropathy Due to Local Malignant Invasion of the Maxillary and Mandibular Nerves at the Skull Base: A Case Report With...

Marketreports.info has released a report titled Global Lebers Hereditary Optic Neuropathy Drug Market that includes industry growth factors for the projected period of 2022-2030. The information looks at a significant global Lebers Hereditary Optic Neuropathy Drug market, the dynamics driving it, the factors restraining it, and the opportunities for growing demand.

The full report appropriately depicts the geographic coverage of the global Lebers Hereditary Optic Neuropathy Drug market. This study provides a benchmark analysis based on corporate insights, distribution channels, market share, regional presence, business strategy, leveraged buyouts, technological advances, recent news, joint projects, agreements, SWOT analysis, and critical financial data.

DOWNLOAD FREE SAMPLE REPORT: marketreports.info/sample/16173/Lebers-Hereditary-Optic-Neuropathy-Drug

The regions and countries are discussed in the global Lebers Hereditary Optic Neuropathy Drug market report:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Segments covered in this report are:

Segment by Type Elamipretide GS-011 IXC-201 KH-176 OthersSegment by Application Hospital Clinic Others

They are the key players profiled in the global market report:

Alkeus Pharmaceuticals Inc., Biovista Inc., GenSight Biologics S.A., Ixchel Pharma LLC, Khondrion BV, Spark Therapeutics Inc., Stealth BioTherapeutics Inc.

ACCESS FULL REPORT: marketreports.info/industry-report/16173/Lebers-Hereditary-Optic-Neuropathy-Drug

The study examines global Lebers Hereditary Optic Neuropathy Drug market trends, inflation rates, driving factors, and competition intensity by segment. The news gathers first-hand knowledge, descriptive and analytical assessments by industry analysts, and input from professionals in the field and content providers at all phases of the manufacturing process.

One of the most critical factors in collecting this report was its correctness and statistics research methodology. The data is combined with a diverse mix of experience, analytics, machine learning, and data science to produce research approaches that result in a various yet accurate analysis of the worldwide Lebers Hereditary Optic Neuropathy Drug market.

Important Questions Answered:

Which Lebers Hereditary Optic Neuropathy Drug market segments are attracting the most attention?

Who are the major market players contending with and developing in the Lebers Hereditary Optic Neuropathy Drug market?

Customization of the Lebers Hereditary Optic Neuropathy Drug Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketreports.info), who will ensure that you get a report that suits your needs. You can also get in touch with our executives directly to share your research requirements.

About Us

Marketreports.info is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in today's competitive environment and thus, we have collaborated with industry's leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact Us:

CarlAllison (Head of Business Development)

Tiensestraat 32/0302,3000 Leuven, Belgium.

Market Reports

phone:+44 141 628 5998

Email: sales@marketreports.info

Website: http://www.marketreports.info

Link:
Global Leber's Hereditary Optic Neuropathy Drug Market 2022 to 2031 Analysis themobility.club - themobility.club

Vitamin B12 is an important B vitamin. It is one of the most important vitamins in maintaining the nervous system, and also plays a crucial role in a variety of bodily processes, including:

However, despite its importance, in the United States and United Kingdom, approximately six per cent of adults aged 60 or younger have a vitamin B12 deficiency. The rate jumps to 20 per cent in people older than 60.

The danger with this, according to the NHS, is that consistently low levels of B12 can cause "damage" to parts of the nervous system, and can even progress to irreversible neurological issues if left untreated. For example, a b12 deficiency can lead to peripheral neuropathy.

According to the NHS, the main symptoms of peripheral neuropathy in your feet include:

Video Unavailable

Click to playTap to play

Play now

"These symptoms are usually constant, but may come and go," explains the health body. As MyLondon reported recently, it's important to see your GP if you're experiencing any of the above symptoms.

Pernicious anaemia is the most common cause of vitamin B12 deficiency in the UK. Pernicious anaemia is an autoimmune condition whereby your immune system attacks the cells in your stomach that produce the intrinsic factor, which means your body is unable to absorb vitamin B12.

B12 is naturally found in:

Plant-based sources of vitamin B12 include yeast extract (such as Marmite) fortified plant milks and fortified breakfast cereals.

"If youre following a plant-based diet, taking a vitamin B12 supplement can help prevent a deficiency," says Holland and Barrett. "Breast-feeding mothers could also consider a supplement, as they need an extra 0.5mcg a day."

As it explains, older people, or those taking medication to reduce production of stomach acid, may need a B12 supplement to boost absorption. Most cases of vitamin B12 and folate deficiency can be easily treated with injections or tablets to replace the missing vitamins, the NHS says.

Vitamin B12 supplements are usually given by injection at first. Then, depending on whether your B12 deficiency is related to your diet, you'll either require B12 tablets between meals or regular injections.

These treatments may be needed for the rest of your life. In some cases, improving your diet can help treat the condition and prevent it coming back.

For more stories from where you live, visit InYourArea.

The rest is here:
Risks of vitamin B12 deficiency and the symptoms to look out for - My London

NeuraLace Medical has announced the expansion of its global patent portfolio with the issuance of two new patents: US Patent No. 11,305,130for Devices, systems, and methods for non-invasive chronic pain therapy (issued19 April 2022) and US Patent No. 11,273,317 for Portable transcutaneous magnetic stimulator and systems and methods of use thereof (issued15 March 2022).

The new patents include system and method claims for treating peripheral nerve pain using low-frequency transcutaneous magnetic stimulation, including advanced applications in wearable pain therapy technology, as per a NeuraLace press release.

The patents, which last until 2039 and 2033, respectively, are part of a global patent portfolio protecting the companys non-invasive, non-pharmacological Axon therapy and advanced applications, such as robotics for applying Axon Therapy, including US Patent No. 10,369,373 issued on 6 August 2019 and US Patent No. 11,058,887 issued on 13 July 2021.

We are pleased to strengthen our intellectual property protection with the addition of these new US patents, saidKeith Warner, CEO of NeuraLace. Along with our robust international IP [intellectual property] portfolio, these patents bolster and expand the protection of our core Axon technology, highlighted by the use of transcutaneous magnetic stimulation as opposed to invasive and/or pharmacologicalsolutions.The companys clinical results thus far have been impressive, and we look forward to this momentum carrying forward to the completion and publication of our formal clinical studies.

The company details in the release that it is in the process of expanding sites of its ongoing randomised clinical trial focusing on the application of Axon therapy to treat neuropathic pain broadly, while also initiating a large study focusing on peripheral diabetic neuropathy.

Here is the original post:
NeuraLace announces two new patents for Axon neuropathic pain therapies - NeuroNews International

Neuropathic pain Growth 2021-2030, Covid19 Outbreak Impactresearch report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. It places the market within the context of the wider neuropathic pain, and compares it with other markets., market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, neuropathic pain size forecast, market data & Graphs and Statistics, Tables, Bar &Pie Charts, and many more for business intelligence.Getcomplete Report (Including Full TOC, 100+ Tables & Figures, and Chart). In-depth Analysis Pre & Post COVID-19 MarketOutbreak Impact Analysis &Situation by Region

The global neuropathic pain market is expected to exhibit a growth rate of 6.06% CAGR during the forecast period 2018- 2023.

A release on June 8th, 2021, by the Bureau and Economic Analysis and U.S. The Census Bureau reports the recovery of the U.S. market. The report also described the recovery of U.S. International Trade in July 2021.In April 2021, exports in the country reached $300 billion, an increase of $13.4 billion. In April 2021, imports amounted to $294.5 billion, increasing by $17.4 billion. COVID19 is still a significant issue for economies around the globe, as evidenced by the year-over-year decline in exports in the U.S. between April 2020 and April 2021 and the increase in imports over that same period of time. The market is clearly trying to recover. Despite this, it means there will be a direct impact on the Healthcare/ICT/Chemical industries, resulting in a large market forNeuropathic pain.

Neuropathic pain is generally caused by the peripheral nerve disorder. The higher demand for better treatment methods for pain is hopefully expected to augment the growth of the global neuropathic pain market during the forecast period 2018- 2023. Also, factors such as the introduction of the pain management centers along with higher demand for generic drugs for eliminating the higher levels of pain is anticipated to boost the growth of the global neuropathic pain market.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=31837

Market segmentation

Based on its type, the global neuropathic pain market is bifurcated into entrapment neuropathy, peripheral neuropathy, post traumatic neuropathy, post herpetic neuralgia (PHN), phantom limb pain, and trigeminal neuralgia. On the basis of its indication, the market is divided into diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and spinal stenosis. Based on its diagnosis, the market is segmented into blood tests, imaging, and physical examination. On the basis of its treatment, the market is classified into medication type and multimodal therapy. Major end-users include clinics, hospitals, and research organizations. Lastly, on the basis of its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.

Regional analysis

Geographically, the global neuropathic pain market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others are some of the major players in the global neuropathic pain market.

Table of Contents:Market Overview Market Dynamics Associated Industry Assessment Market Competitive Landscape Analysis of Leading Companies Market Analysis and Forecast, By Product Types Market Analysis and Forecast, By Applications Market Analysis and Forecast, By Regions Conclusions and Recommendations Appendix

Access full Report Description, TOC, Table of Figure, Chart, etc. @https://reportocean.com/industry-verticals/sample-request?report_id=31837

Our market research provides vital intelligence on market size, business trends, industry structure, market share, and market forecasts that are essential to developing business plans and strategy.

A combination of factors, including COVID-19 containment situation, end-use market recovery & Recovery Timeline of 2020/ 2021

Under COVID-19 Outbreak Impact Analysis:We analyzed industry trends in the context of COVID-19. We analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets. We analyze the impact of COVID-19 on various regions and major countries.The impact of COVID-19 on the future development of the industry is pointed out.

The Study ExploreCOVID 19 Outbreak Impact AnalysisWhat should be entry strategies, countermeasures to economic impact, and marketing channels? What are market dynamics? What are challenges and opportunities? What is economic impact on market? What is current market status? Whats market competition in this industry, both company, and country wise? Whats market analysis by taking applications and types in consideration?

Key questions answered:Study ExploreCOVID 19 Outbreak Impact Analysis

The study objectives of this report are:To study and analyse the global market size (value & volume) by company, key regions/countries, products and application, history data, and forecast to 2025. To understand the structure of market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global manufacturers, to define, describe and analyse the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyse the growth trends, future prospects, and their contribution to the total market. To project the value and volume of submarkets, with respect to key regions (along with their respective key countries). To analyse competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.

Request Full Report-https://reportocean.com/industry-verticals/sample-request?report_id=31837

What is the key information extracted from the report?

Geographical Breakdown:The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery path of Covid 19 for all regions, key developed countries and major emerging markets.

Countries:Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam

In-Depth Qualitative COVID 19 Outbreak Impact Analysis Include Identification And Investigation Of The Following Aspects:Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces. The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios. The report basically gives information about the Market trends, growth factors, limitations, opportunities, challenges, future forecasts, and details about all the key market players.

Request Full Report-https://reportocean.com/industry-verticals/sample-request?report_id=31837

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Report Ocean:

Email:sales@reportocean.com

Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.reportocean.com/

See the original post here:
Neuropathic pain Market Overview By Share, Size, Industry Players, Revenue and Product Demand 2021-2030 The New York Irish Emgirant - The New York...

Posted: Nov 15, 2021 / 12:24 PM CST / Updated: Nov 15, 2021 / 12:24 PM CST

According to ClevelandClinic.org, over 100 million people suffer from neuropathy. The condition affects people of all ages but the most vulnerable are older Americans.

Dr. Jarrod Bagley, D.C., founder of Corrective Health, joined Studio 512 Co-Host Rosie Newberry to talk about peripheral neuropathy and how he can help.

Dr. Bagley, how are the nerves affected by neuropathy?

Nerves in the body become damaged and send signals to the brain that translate into pain.The body has a peripheral nervous system that sends signals to the brain and the central nervous system. The damage occurs over time. So, it isnt necessarily something that happens overnight. Therefore, the symptoms, such as a prickly feeling, burning, or tingling in the hands or feet, gradually increase over time.

What things trigger neuropathy?

There are several types of neuropathies.One of the most common forms comes from having diabetes and results from not managing the disease properly.For example, a consistent high level of blood sugar.Also, low vitamin levels, chemotherapy, and even alcoholism can contribute to neuropathy.

Can neuropathy be reversed?

The good news is that in most cases it can be reversed with natural, non-invasive treatments. We can reverse the damage if it has not reached 80% nerve loss. Neuropathy, if not treated by a professional, could lead to being confined to a walker or wheelchair and even amputation. It is important to get evaluated sooner than later. Corrective Health uses no drugs, no injections, and no surgeries. In fact, we have the most advanced non-surgical FDA-cleared treatments available that focus on regenerating nerves and arteries.

I understand you have an offer for our viewers.A $49 Neuropathy Special?

Yes, that includes a personal consultation, exam, and report of findings.

$49 Neuropathy Special for the first 25 callers (retail value of $249.00), which includes a personal consultation with a physician, complete exam, report of findings. Call Corrective Health at 512-263-0040.

That is a great offer for folks suffering from neuropathy.

During the exam, we calculate down to the exact percentage of how much sensory loss you have in your hands and feet. Its critical to calculate the sensory loss early because once you have reached a certain point nothing can be done.

Doctor, if someone is suffering from neuropathy, how soon can they be seen?

We have trained staff ready to address the specific needs and treatments of each patient. Give us a call.There is no reason to live in pain.

If you or someone you know suffers from chronic pain or neuropathy, call 512-263-0040. First 25 callers are eligible for the $49 Neuropathy Special. Visit CorrectiveHealthATX.com to learn more.

This segment is paid for by Corrective Health and is intended as an advertisement. Opinions expressed by the guest(s) on this program are solely those of the guest(s) and are not endorsed by this television station.

See the original post:
Find Help For Peripheral Neuropathy With Corrective Health - KXAN.com

PARIS--(BUSINESS WIRE)--France-based biotechnology company AlgoTherapeutix, developer of ATX01, an innovative topical treatment for the pain of peripheral neuropathy, announced today that the ATX01 Phase I trial successfully reached its safety and pharmacokinetics objectives, clearing the way for Phase II development in Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Stphane Thiroloix, Founder & CEO of AlgoTherapeutix, comments : The outcome of this Phase I trial is an important milestone for AlgoTherapeutix. We are delighted that ATX01s innovative approach and formulation did not raise any safety concern, and its PK profile is consistent with our objectives. We are now busy preparing for the pivotal Phase II CIPN study.

Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the feet and hands: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause of modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.

A recent publication in the Journal of Pain describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002)

About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. In 2020, AlgoTherapeutix raised a 12 M Series A led by Bpifrance and Omnes Capital to move its lead program ATX01 into clinical development. ATX01 is Phase II ready in painful peripheral neuropathy.

More information on AlgoTherapeutix : http://www.algotx.com

Visit link:
AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022 - Business Wire

Latest Report on Diabetic Neuropathy Treatment Market size | Industry Segment by Applications (Hospitals , Clinics and Others), by Type (Peripheral Neuropathy , Autonomic Neuropathy , Proximal Neuropathy and Focal Neuropathy), Regional Outlook, Market Demand, Latest Trends, Diabetic Neuropathy Treatment Industry Growth & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2026. Analyzes current market size and upcoming 5 years growth of this industry.

The investors, stakeholders, emerging and established players can leverage the data included in the report to develop impactful growth strategies and improve their position in the current Diabetic Neuropathy Treatment Market landscape. The report provides a thorough assessment of the micro and macro-economic factors that are expected to impact the growth of the Diabetic Neuropathy Treatment Market.

It provides detailed knowledge of upcoming market trends and current conditions in the global market. This report covers the past, present and forecast period for the long-term and collective examination of the Diabetic Neuropathy Treatment market.

Request Sample Copy of this Report @ https://www.nwdiamondnotes.com/request-sample/74964

Pivotal players studied in the Diabetic Neuropathy Treatment Market report:

Propelling Factors & Challenges:

The report provides data associated with the forces influencing the commercialization scale of the global Diabetic Neuropathy Treatment market for and their effect on the revenue graph of this business vertical. The latest trends driving the market along with the challenges this industry is about to experience in the upcoming years are mentioned in the report. The report emphasizes the key driving and restraining forces for this market. The research report sheds light on development factors, business enhancement strategies, statistical growth, financial gain or loss.

By the product type, the market primarily split into:

By the product Applications, the market primarily split into:

Valuable Market Insights Included in the Report

The report addresses the following queries related to the Diabetic Neuropathy Treatment Market

Global Diabetic Neuropathy Treatment Market Pinpoints:

Request Customization on This Report @ https://www.nwdiamondnotes.com/request-for-customization/74964

Follow this link:
Diabetic Neuropathy Treatment Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Northwest Diamond Notes

Diabetes impacts more than 4.9 million people in the UK, with 90 percent of those cases type two, according to diabetes.org. Though diabetes can be managed, if blood sugar levels are left to spike over long periods of time, it can lead to further conditions.

Long-term blood sugar levels can end up causing severe damage to the nerves.

In particular, nerves that receive signals from your hands and feet can be the most affected.

This is known as diabetic neuropathy, an additional condition that currently has no known cure.

Though around 50 percent of people with diabetes may experience nerve pain at some point in their life, it is not always as severe as diabetic neuropathy.

Most often, it is felt as a "tingling sensation" in the hands and feet, according to Healthline.

READ MORE:Signs of autism in adults - the 8 unique personality traits

"Peripheral neuropathy becomes more likely the longer you have had diabetes.

"Up to one in four people with the condition experience some pain caused by nerve damage."

However, the NHS notes that it can occur for reasons other than diabetes.

The NHS explains: "In some cases, no cause can be identified and this is termed idiopathic neuropathy."

If you have diabetes, your risk for additional side effects are higher if you smoke, drink large amounts of alcohol regularly, or are over the age of 40.

Diabetic neuropathy, though often felt as a tingling feeling, can also feel like numbness.

Fingers, toes, hands and feet are most often affected.

In some cases, burning, sharp or aching pains can be felt in the impacted parts of the body.

Pain may begin mild and grow stronger over time, possibly extending up the arms and legs.

There is no current known cure for the condition.

Instead, the focus of treatment is on maintenance and reducing symptoms worsening.

Options include diet changes, regular exercise and some medications, which can help to reduce blood sugar levels and relieve pain.

Read the original:
Diabetes: The 'tingling' sensation that can be caused by long-term high blood sugar - Daily Express

Nov. 19There's a life-altering infection out there that's plaguing people 65 and older, but it's not the novel coronavirus.

It's shingles, which is recognizable by a painful rash and blisters that scab and pus. While it looks like a skin rash to the naked eye, it's actually an infection to the nerve tissue buried beneath the skin, initiated by the same virus that causes the scourge of most children chickenpox.

"(It's) not a fun thing," said Neosho resident Karol Meyers, who suffered through a round of shingles recently. "(I'm) hoping I don't ever get it again."

Shingles should never be taken lightly or brushed aside, said Dr. Henry Petry, geriatrician with Freeman Center for Geriatric Medicine.

"Almost all of the people who get it have had chickenpox in their lifetime," he said. "The older you are, the more likely you are to get it. Recent (Centers for Disease Control and Prevention) studies state that 1 out of 3 people probably the age of ... 65 or above are probably going to get it."

When shingles first breaks out, "it is very painful," Petry said. The rash mostly centered on the chest or abdomen, but it can also appear on the head or face a few days following the onset of pain "can blister, and it's usually linear, meaning it goes from the back (of the body or head) to the front."

During that time, people will feel varying degrees of pain, which can flare up anywhere on the body where there are nerves. When shingles "gets back (in the nerves) it's like an infection in that area, and it kind of inactivates it and makes it do funny things it's not supposed to do," he said.

When treated, an episode can last between seven and 10 days. If untreated, "there's the possibility of developing a type of neuropathy," which is damage or dysfunction of one or more nerves that result in sporadic pain, numbness, tingling and muscle weakness for years on end, Petry said.

Story continues

"I've had a couple of (patients) who had it, but they didn't get (shingles) around the chest but down their leg, and they developed permanent foot drop from the changes to the sciatic nerve," he said. Petry also said that should the rash appear on the face and blisters form in the eye, it can cause blindness.

These long-term complications of pain and dysfunction "can be very devastating to the quality of life of that person if it's not treated," he said. "The older you are, the more likely you'll have a problem with it."

While it's impossible for two people who previously had chickenpox to pass shingles to one another, it is possible for someone with shingles to pass it to someone who has never previously had chickenpox, he said.

To that end, CDC officials have noticed a slight increase in shingles cases over the past 24 months, most likely due to stresses brought on by COVID-19.

"Stress is a big immune system depressant," Petry said. "Any time that you have a change in your immune system ... that suppresses it, it's down; I don't mean depressed, but you're down" physically. Major stresses, and some back-to-back-to-back stressors lasting for years, "can make your immune system more susceptible to everything, even to the common cold."

There are ways to lessen the risks from shingles. There are three different types of antiviral drugs that work effectively to rid the body of the infection; steroids also help to reduce some of the post-shingles neuropathy symptoms.

But the best and safest way to protect oneself from shingles is to get immunized against it. CDC officials recommend that healthy adults 50 and older get the two-dose vaccine Shingrix. The vaccine, which two years ago replaced a single-dose vaccine, is more than 90% effective at preventing shingles.

Vaccination against shingles "is the one thing that we really, really recommend as you get older ... in order to prevent the spread of it so it can't be a life-altering infection," Petry said.

Kevin McClintock is features editor for The Joplin Globe.

Follow this link:
Vaccinations urged against shingles, a viral infection that's on the rise - Yahoo News

Broadway Vascular

Broadway Vascular

SAN ANTONIO, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Broadway Vascular today announced top-line data from a retrospective analysis of Dr. Broadway's revolutionary revascularization technique, involving treating of the lateral plantar artery for treatment of diabetic neuropathy.

Background:

Diabetic neuropathy is a common and debilitating condition for which available treatments are limited. Arterial stenosis or occlusion (blocking of the artery) is the reason behind nerve death and neuropathy. This results in the symptoms of diabetic neuropathy. Dr. Broadway hypothesized that revascularization of the lateral plantar artery will result in regrowth of the nerve fibers, restoring sensation, therefore, treating diabetic neuropathy.

Methods:

In this 12-month retrospective study, individuals with type 2 diabetes and painful diabetic neuropathy were evaluated. The intervention included revascularization of the lateral plantar artery using an atherectomy device with balloon angioplasty. At baseline, all patients complained of neuropathy with burning, tingling or pain. All were confirmed to have neuropathy. Third-party questionnaire data was collected.

Results:

After 12 months, 22 patients were contacted. Twenty-one of the 22 reported improved Quality of Life. Sixteen of the 22 demonstrated significant improvement of symptoms and neuropathy. Five of the 22 demonstrated complete resolution of neuropathy. One patient did not improve. Ages treated ranged from 50-90 years of age. HbA1c treated were 6.3 to 10.6%.

Conclusions:

Improvements were seen in 95% of patients. This retrospective study suggests the potential value of revascularization of the lateral plantar artery for treating diabetic neuropathy.

Diabetic peripheral neuropathy occurs in up to 60% of individuals with type 2 diabetes and is associated with significant morbidity, including gait disturbances, amputations, anxiety, depression and reduced quality of life. The condition manifests with damage to the terminal branches of peripheral nerves and usually first affects small fibers that are responsible for translating pain, light touch and temperature. As neuropathy progresses, large fibers responsible for reflexes and muscle tone are affected, leading to balance and gait problems. Most patients with diabetic peripheral neuropathy present with pain, numbness, or abnormal, spontaneous or induced sensations in the lower extremities1.

Story continues

Broadway Vascular is excited to bring to the community this option to help patients improve their quality of life. They understand more studies are needed to validate this treatment. An ongoing study that Broadway Vascular is conducting evaluates nerve regrowth. In this study, patients will have nerve biopsies before and after their treatment.

About Broadway Vascular:

Broadway Vascular, a pioneering and boutique medical practice, offers non-surgical treatments for many endovascular diseases, such as: peripheral arterial disease, enlarged prostate, knee pain, and bleeding from fibroids or hemorrhoids. They also bring extensive experience with renal failure and caring for patients on hemodialysis.

If persons have a history of diabetes, neuropathy, cold feet, hair loss on legs or feet, pain in legs, pain in feet, smoking, high blood pressure, high cholesterol, call Broadway Vascular at 210-465-7015 to see how they can help you or become part of this study.

For more information on Broadway Vascular's office, located at Blanco Road and Interstate 410 in San Antonio, please visit https://broadwayvascular.com.

For More Information Contact:

Helen Ganzehganze@broadwayvascular.com(210) 465-7015

1. Bunner, A., Wells, C., Gonzales, J. et al. A dietary intervention for chronic diabetic neuropathy pain: a randomized controlled pilot study. Nutr & Diabetes 5, e158 (2015). https://doi.org/10.1038/nutd.2015.8

Related Images

Image 1: Broadway Vascular

This content was issued through the press release distribution service at Newswire.com.

Attachment

Read more here:
Broadway Vascular Announces Top-Line Results of 12-Month Retrospective Analysis Evaluating Revascularization of the Lateral Plantar Artery in Diabetic...

Substantial and significant reduction in sorbitol

Company plans to initiate registrational trial by end of 2021

Company to host conference call and webcast today at 8:30 a.m. ET

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported biomarker data from a pilot trial of AT-007 in patients with SORD Deficiency.

Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a rare, progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons. SORD Deficiency affects approximately 3,300 patients in the US and 4,000 patients in Europe. The disease is caused by a lack of the enzyme sorbitol dehydrogenase, responsible for metabolism of sorbitol, which causes sorbitol to accumulate at high levels and become toxic to the body. Sorbitol accumulation results in significant disability, loss of sensory function, and neuromuscular dysfunction.

Patients with SORD Deficiency have 100 times higher sorbitol concentration in their blood compared with unaffected individuals. In a pilot open-label study in 8 SORD Deficiency patients, AT-007 reduced blood sorbitol levels by approximately 66% from baseline through 30 days of treatment. The range of reduction from baseline in patients was 54%-75%. AT-007 was safe and well tolerated in all treated patients.

These results, in addition to preclinical findings, demonstrate that AT-007 has the potential to be the first disease-modifying therapy for SORD Deficiency. The Company plans to initiate a registrational study by the end of 2021. In advance of the registrational study start, patients can now pre-screen to determine whether they have SORD and if they may qualify for the upcoming trial.

Reduction in toxic sorbitol is critically important in patients with SORD Deficiency. This data demonstrates a significant effect on the underlying cause of the disease, said Michael Shy, MD, Professor of Neurology and Director of the Division of Neuromuscular Medicine at the University of Iowa Hospital Carver School of Medicine.

Story continues

AT-007 represents an important advancement for patients with SORD Deficiency, and a unique opportunity to meaningfully impact patients lives. We look forward to beginning our registrational trial for this indication in the coming months, said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics.

Increased access to screening and early diagnosis can dramatically improve patients lives, and the Company is collaborating with the Charcot Marie Tooth Association and the Hereditary Neuropathy Foundation to improve access to SORD diagnostic testing, and to better understand the perspectives of individuals living with SORD.

Conference Call Information

Applied Therapeutics will host a conference call today, Monday, October 25, 2021, at 8:30 a.m. Eastern Time, to discuss data from a pilot trial of AT-007 in SORD deficiency. To access the conference call, please dial (800) 369-8554 (local) or (409) 937-8917 (international) at least 10 minutes prior to the start time and refer to conference ID 2437605. A live webcast of the call will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at http://www.appliedtherapeutics.com. A replay will be available on the Companys website approximately two hours after the event.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companys lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

To learn more, please visit http://www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as may, will, expect, anticipate, plan, intend, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Companys plan to initiate a registrational study by the end of 2021, (ii) AT-007 potential to be the first disease-modifying therapy for SORD Deficiency, (iii) the timing of the initiation and completion of our clinical trials, (iv) the likelihood that data from our clinical trials will support future development of our product candidates and (v) the likelihood of obtaining regulatory approval of our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.

Such risks and uncertainties include, without limitation, (i) our plans to develop and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain regulatory approval of our current and future product candidates, (viii) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (ix) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (x) the implementation of our business model and strategic plans for our business and product candidates, (xi) our intellectual property position and the duration of our patent rights, (xii) developments or disputes concerning our intellectual property or other proprietary rights, (xiii) our expectations regarding government and third-party payor coverage and reimbursement, (xiv) our ability to compete in the markets we serve, (xv) the impact of government laws and regulations and liabilities thereunder, (xvi) developments relating to our competitors and our industry, (xvii) the impact of the COVID-19 pandemic on the timing and progress of our ongoing clinical trials and our business in general and (xviii) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the Risk Factors contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Contacts

Investors:Maghan Meyers(212) 600-1902 orappliedtherapeutics@argotpartners.com

Media:media@appliedtherapeutics.com

Patients:SORD@appliedtherapeutics.comDottie Caplan, SVP Patient Advocacy and Engagementdcaplan@appliedtherapeutics.com617.417.8114

Applied Therapeutics, Inc.

Read more:
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency - Yahoo Finance

Uttar Pradesh has reported a case of the Zika virus, which caused havoc in Kerala a few months ago. The Centre has dispatched a multi-disciplinary team to Kanpur in UP where an Indian Air Force personnel tested positive with Zika on October 23.

The local authorities in Kanpur have formed multiple teams and started implementing precautionary action in the affected person's his residential area and the workplace.

According to Kanpur chief medical officer (CMO) Nepal Singh said, as many as 22 samples of people the patient came in contact with have been sent to National Institute of Virology (NIV) in Pune for examination.

What is Zika virus?

The World Health Organization (WHO) defines Zika virus as a mosquito-borne flavivirus that was first identified in Uganda in 1947 in monkeys. It was later identified in humans in 1952 in Uganda and Tanzania, it further said.

The global health body has recorded outbreaks of Zika virus disease in Africa, the Americas, Asia and the Pacific.

Transmission

Zika virus is primarily transmitted by the bite of an infected mosquito from the Aedes genus, mainly Aedes aegypti. These mosquitoes usually bite during the day, peaking during early morning and late afternoon/evening.

This is the same mosquito that transmits dengue, chikungunya and yellow fever.

Zika virus is also transmitted from mother to fetus during pregnancy, through sexual contact, transfusion of blood and blood products, and organ transplantation.

Symptoms

The symptoms of the disease caused by the Zika virus are mild fever, rash, conjunctivitis, muscle and joint pain, malaise or a headache and usually last for 2-7 days.

The symptoms are very similar to other disease. Zika received special attention after the 2015-2016 outbreak in Brazil.

Treatment

No vaccine is yet available for the prevention or treatment of Zika virus infection. Development of a Zika vaccine remains an active area of research, according to WHO.

How to prevent yourself from Zika?

Protection against mosquito bites during the day and early evening is a key measure to prevent Zika virus infection. Special attention should be given to prevention of mosquito bites among pregnant women, women of reproductive age, and young children.

The WHO recommends wearing clothing (preferably light-coloured) that covers as much of the body as possible; using physical barriers such as window screens and closed doors and windows; and applying insect repellent to skin or clothing.

Things to know about Zika virus disease

According to the Centers for Disease Control (CDC) in the United States, Zika is linked to birth defects. Its infection during pregnancy can cause a serious birth defect called microcephaly that is a sign of incomplete brain development.

Zika virus infection is also a trigger of Guillain-Barr syndrome, neuropathy and myelitis, particularly in adults and older children. The infection in pregnancy also results in complications such as fetal loss, stillbirth, and preterm birth.

It also said that returning travellers infected with Zika can spread the virus through mosquito bites and sex. The CDC, in one of its advisories, said that even if the travellers do not feel sick, after returning from an area with risk of Zika, they should take steps to prevent mosquito bites for three weeks so they do not spread Zika to uninfected mosquitoes.

Continue reading here:
Zika virus in UP: Symptoms, treatment and other things to know - Hindustan Times

Alger, an investment management firm, published its Alger Small Cap Focus Fund third quarter 2021 investor letter a copy of which can be downloaded here. During the third quarter, the largest portfolio sector weightings were Health Care and Information Technology. The largest sector overweight was Health Care. The portfolio had no exposure to the Financials, Materials, Real Estate, or Utilities sectors. You can take a look at the funds top 5 holdings to have an idea about their best picks for 2021.

Alger, in its Q3 2021 investor letter, mentioned Nevro Corp. (NYSE: NVRO) and discussed its stance on the firm. Nevro Corp. is a Redwood City, California-based medical device company with a $4.2 billion market capitalization. NVRO delivered a -29.93% return since the beginning of the year, while its 12-month returns are down by -25.08%. The stock closed at $121.29 per share on October 22, 2021.

Here is what Alger has to say about Nevro Corp. in its Q3 2021 investor letter:

"Nevro Corp. was among the top detractors from performance. Nevro has developed and commercialized a proprietary high frequency spinal cord stimulation (SCS) system. More broadly, this technology is known as neuromeodulation, which involves treating pain with electrical stimulation. Today, Nevro's technology is primarily used to treat chronic lower back and leg pain. However, the company received FDA approval to use its system for the treatment of chronic pain associated with painful diabetic neuropathy (PDN) in July, which represents a potentially significant market opportunity. We believe Nevros underperformance resulted from the company producing weaker-than-expected results for the three-month period ended June 30 and, more importantly, issuance of guidance for the third quarter that was well below investor expectations. The company also withdrew full-year revenue guidance due to limited visibility regarding COVID-19 related recovery trends and timelines. For the third quarter guidance, Nevro attributed its disappointing outlook to the impact of the pandemic and a slow recovery in procedure volumes as patients appear to be holding off on physician office visits and surgeries. However, investors have also been concerned that Nevro may be losing share to competitors and that SCS market growth has moderated. We have sold the position."

Story continues

Romaset/Shutterstock.com

Based on our calculations, Nevro Corp. (NYSE: NVRO) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. NVRO was in 26 hedge fund portfolios at the end of the first half of 2021, compared to 29 funds in the previous quarter. Nevro Corp. (NYSE: NVRO) delivered a -21.28% return in the past 3 months.

Hedge funds reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldnt keep up with the unhedged returns of the market indices. Our research has shown that hedge funds small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by 115 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium mining is one of the fastest-growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage.

Disclosure: None. This article is originally published at Insider Monkey.

Read the original:
Heres Why Alger Sold its Nevro Corp. (NVRO) Position - Yahoo Finance

Q: AFTER a recent one-hour walk I developed a burning feeling and tingling sensation in both feet, which lasted for most of the evening. I walk every other day and have always worn walking boots and thick socks.

GM

A: THE symptoms you've experienced are known medically as paraesthesia - from the Ancient Greek 'para' for abnormal or irregular, and 'aesthesia' for sensation.

As both feet are affected, it suggests you have peripheral neuropathy, a common condition caused by damage to the peripheral nerves which run from the brain and spinal cord to all parts of the body, including the hands and feet.

This damage can disrupt the passage of messages along these nerves, leading to numbness, and burning and tingling sensations, such as you describe.

It can also cause muscle weakness, but this is less common.

More than a quarter of over-65s will develop peripheral neuropathy at some point, with a number of potential causes.

It can occur as the result of spinal problems (for instance, through nerve compression), or as a side-effect of daily medications such as amiodarone (used to treat heart rhythm problems), metronidazole and nitrofurantoin (both prescribed for infections) and phenytoin (an anticonvulsant) - all of which can affect nerve function.

Peripheral neuropathy can also be a complication of shingles, caused by the herpes zoster virus which travels via the nerves.

However, the main cause is diabetes as a result of high blood sugar levels over time damaging the nerves.

So, in the first instance, it is important to ask a few questions: did you experience any weakness in your legs during the walk?

And following the evening when you noticed the pain, were there any residual sensations the next day, or since?

Did you have backache, and/or do you have any seemingly unrelated health problems, such as diabetes, or take daily medications?

If you answer yes, and if your symptoms recur and persist, I would suggest seeing your GP.

Diagnosing peripheral neuropathy can involve a nerve conduction study, where an electrode which produces tiny electrical pulses is placed on the leg, and how well these travel down the nerve is measured.

The treatment for the condition depends on the underlying problem causing it.

Some people with migraine don't experience headaches at all, but do suffer a complete loss of energy

Q: MY granddaughter, now 15, has had a 'weird illness' monthly since she was nine. I can only describe it as a total physical collapse which lasts a few days, with headaches and no energy. It's not premenstrual tension (PMT) and neither the GP nor a psychologist can diagnose it, although blood tests show raised markers.

NA

A: I agree, the regularity of these monthly episodes, taking place 10 days after her period (as you explain in your longer letter) and the total loss of energy and collapse are odd symptoms.

My suggestion is that your granddaughter is suffering from a form of migraine - in her case, the headaches aren't the most significant feature of her attacks. (In fact, some people with migraine don't experience headaches at all.)

In some sufferers, migraine can also cause a complete loss of energy, making them feel exceedingly unwell, with other widespread sensations that are difficult to describe and that sometimes last for three to four days. Patients can also experience nausea or loss of appetite.

As there are no specific diagnostic tests for migraine, it might be worth her trialling one of the triptan drugs (e.g. sumatriptan). These trigger the production of serotonin, a hormone that constricts blood vessels and reduces inflammation.

They are not licensed for children but can be used 'off label' under supervision.

A small dose of sumatriptan, 25mg, under the advice of her GP or paediatrician, could be worth trying, and prove if this suggested diagnosis is correct.

It is a good idea to use a cheap and simple blood pressure monitor at home

IN MY VIEW: We must all know our blood pressure

NOT enough people realise that high blood pressure is a silent killer - no doubt due to the fact that even very high blood pressure causes nothing in the way of symptoms, but by then there's so much damage that full recovery is impossible.

As well as heart attacks, it can lead to the arteries rupturing, causing a stroke - resulting in massive damage or death.

This is why screening for high blood pressure is vital.

One obstacle to accurately monitoring it is that blood pressure is labile - i.e. it jumps about - and some people's jumps up the minute they enter the surgery or set eyes on a doctor, so-called 'white coat' hypertension.

So I applaud the fact that the over-40s can now get free blood pressure checks at chemists. It may well be that the psychologically driven reflex that results in higher pressures when tested at a doctor's surgery will not occur.

Even better, I think, is to buy a simple and cheap blood pressure monitor and to use this at home every few days (or, if your readings are normal, maybe once a month).

That way you'll get the most relaxed - and the most realistic - readings.

Nobody should be seeing regular measurements of blood pressure higher than 140/90.

Daily Mail

Original post:
Ask the GP: Why do my feet feel like they're on fire? - The Irish News

Steven Miller| Guest columnist

The Department of Veterans Affairs announcedOct.13that it is preparing to hire more than 2,000 new employees to assist in disability claims processing.

According to the VA, more than 204,000 backlogged disability claims are in the Veterans Benefits Administrations' disability claims queue.Many of the claims result from the VA adding three new diseases to the Agent Orange presumptive list. The presumptive list contains the diseases that the VA will presume to have been caused by exposure to Agent Orange.

The three new conditions are hypothyroidism, bladder cancer, and Parkinsonism. With the three new conditions, the VA now recognizes 17diseases caused by Agent Orange exposure. The other diseases areAL amyloidosis, chronic B-Cell leukemias, chloracne, diabetes mellitus type 2, Hodgkins disease,ischemic heart disease, multiple myeloma, non-Hodgkins lymphoma, Parkinson's disease, peripheral neuropathy (either secondary to diabetes or having occurred within one year of leaving Vietnam), porphyria cutanea tarda, prostate cancer, respiratory cancers and soft tissue sarcomas.

If you need assistance filing a VA disability claim or if you have questions about federalstate, or local veterans benefits, please reach out to my office.

Steven Miller is theMonroe County Veteran Service Officer. Callhim at 812-349-2537 or email smiller@co.monroe.in.us.

More:
For veterans: VA prepares to tackle backlogged disability claims - The Herald-Times

Originally known as Neuropathy Treatment Centers of PGH, Tri-State Neuropathy Centers was established in 2013 by Dr. Shawn Richey and served patients only from their Wexford office until 2015 when expansions began. There are now five locations with three of those located in Pennsylvania (Monroeville, Washington, and Wexford), one in Poland, Ohio, and one in Weirton, West Virginia.

Approximately 30 million Americans suffer from peripheral neuropathy and its debilitating symptoms of painful cramping, burning and tingling, numbness in the feet, legs and/or hands, difficulty walking and even interruption of sleep. Tri-State Neuropathys program has had a phenomenal satisfaction rate and has seen thousands of patients suffering with peripheral neuropathy who have tried everything including potentially harmful medications and other painful testing and treatments. This can leave patients still struggling and wandering down the long road of endless disappointment.

With Tri-State Neuropathy Centers innovative treatments, patients now have hope and can have the pain associated with peripheral neuropathy addressed. We have treated over 8,000 patients with a 90% satisfaction rate, and we are confident that we can help improve most anyones life who has been affected by this devastating disease, said Dr. Shawn Richey, CEO, Tri-State Neuropathy Centers.

Tri-State Neuropathy Centers are 100% focused on helping people obtain relief from neuropathy, said Dr. Richey. Our proven treatment protocol is a PAINLESS, NON-INVASIVE AND DRUG-FREE therapy that utilizes advanced technology to reverse the horrible symptoms of peripheral neuropathy. It was once thought that there was no hope for neuropathy sufferers, and now there is.

Paula Connelly sought help in 2020 when her foot became numb after surgery. I was getting very depressed as my foot was numb on the side of the incision and it was affecting my life.I decided to meet with Tri State Neuropathy Centers for a free consultation. I have completed the program I am pain free and 90 percent better. I am 68 and a Grammy of 6 grandchildren.The treatment has helped me walk without a cane and be more active with my active family as my balance has improved tremendously.

Janine Caddys pain was progressing to the point where she couldnt walk. It seems like it became noticeable about 20 years ago. At first my feet would ache from time to time, then my feet would ache so bad that I had to limit my time standing or walking. I could no longer go hiking with my husband or just take a walk. I knew it was just a matter of time before I would need a wheelchair. I heard about Tri-State Neuropathy Centers and went for my free consultation to see if I was a candidate. To date, I see a significant improvement. I can take short walks, cook and I have even been gardening. It feels like a miracle.

Frank Smitts foot condition preventing him from enjoying his usual activities. Ten years ago I hurt my foot and it continued to get worse over the years. It got to the point that my feet were so sore and cold all the time. Outdoor activities are very important to me and I was losing the ability to do them. I felt there was no hope. A friend of mine learned of Tri StateNeuropathy Centers and I made an appointment. The results have been unbelievable. I have no more pain and my feet are no longer cold. My range of motion is so much better, and my balance is back. I am now enjoying all the outdoor activities I use to and am nearly 100% better.

If you are suffering with peripheral neuropathy, you may want to consult Tri-State Neuropathy Centers for a free evaluation. We offer the first initial consultation, examination and first treatment for FREE. We qualify patients to make sure they are candidates for our treatments, and of the over 8,000 patients we have qualified, we have an outstanding success rate, said Dr. Richey.

Patients can call 724-940-9000 to schedule an initial, no-cost consultation to determine if they qualify for the Tri-State Neuropathy Centers treatment program. Additionally, a free confidential online survey is available for patients on the Tri-State Neuropathy website (www.marydancedin.com). Each survey is reviewed by a doctor.

Sponsored content brought to you byTri-State Neuropathy Centers.

Excerpt from:
Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help...

Expanding at 5.9% CAGR, Peripheral Neuropathy to Cement Dominance in Diabetic Neuropathy Treatment Market

The diabetic neuropathy market study by Fact.MR offers compelling insights into key growth drivers and restraints impacting the market through 2031. The survey offers diabetic neuropathy demand outlook and studies opportunities existing in key segments, including type and end user. It also highlights key strategies adopted by market players to increase diabetic neuropathy sales.

Fact.MR A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global market for diabetic neuropathy is anticipated to rise at a CAGR of 5.6% over the forecast period 2021-2031.

Increasing prevalence of diabetes as a result of changing lifestyles and imbalanced diets is a primary factor, supporting the growth of the diabetic neuropathy market. In 2019, it was found that over 1/10th of the worlds population suffered from diabetes.

Considering this, leading manufacturers are increasingly focusing on incorporating anti-diabetic formulations within their diversified portfolio. For instance, Janssen Global Services LLC, a leading pharmaceutical company offers a wide range of drugs including NUCYNTA, NUCYNTA ER, Duragesic and INVOKANA.

These drugs include tapentadol and canagliflozin, which help in regulating the blood sugar levels. Several other leading pharmaceutical companies are expected to join the bandwagon, while expanding their portfolio. These factors will contribute towards the growth of the diabetic neuropathy market.

Request a report sample to gain comprehensive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4698

Among various types of disorders, peripheral neuropathy segment is gaining traction and exhibiting a higher sales of diabetic neuropathy formulations. As per the Fact.MR, demand outlook for peripheral neuropathy remains optimistic and it is set to expand at a CAGR of 5.9% over the upcoming years.

Besides these, hospitals have emerged as dominant end users owing to the availability of advanced infrastructure and healthcare expertise. Also higher footfall patients will continue supporting growth in demand across hospitals.

According to the study, North America is dominating the market for diabetic neuropathy, accounting for nearly 2/5 of the market revenue across the globe. Owing to factors such as increasing number of patients for getting treatment along with rising investment in research for the development of new drugs, the market in the region is expected to expand considerably over the forecast period 2021-2031.

Increasing emphasis on research and development pursuits along with innovations in drug combinations for fulfilling the dual purpose of providing symptomatic pain relief and preventing the progression of neuropathic processes will bolster future growth prospects, says a Fact.MR analyst.

Key Takeaways from Diabetic Neuropathy Market Survey

Key Drivers

Key Restraints

To learn more about Diabetic Neuropathy Market, you can get in touch with our Analyst at:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=4698

Competitive Landscape

Diabetic neuropathy manufacturers are focusing on receiving certifications from international organizations for their new product launches.

In 2017, Pfizer announced that the U.S. Food and Drug Administration (FDA) approves STEGLATRO(ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2)inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets

For instance, in 2020, Lupin Pharmaceuticals Inc, received tentative approval from U.S. health regulator to market type 2 diabetes drugs namely Empagliflozin and Linagliptin tablets.

Some of the leading players operating in the diabetic neuropathy market profiled by Fact.MR are:

More Valuable Insights on Diabetic Neuropathy Market

Fact.MR, in its new report, offers an unbiased analysis of the global diabetic neuropathy market, analysing forecast statistics through 2021 and beyond. The survey reveals growth projections on diabetic neuropathy market with detailed segmentation:

Key Questions Covered in the Diabetic Neuropathy Market Report

Explore Fact.MRs Coverage on the Healthcare Domain

Diabetes Diagnostics Market- The demand for diabetes diagnostics is predicted to increase as a result of the COVID-19 outbreak, which has resulted in an increase in hospitalizations. Diabetes test strips are in high demand as a result of studies that show diabetics are at a higher risk of becoming seriously ill if infected with the virus. Government investment for hospitals will help to expand the market overall by making healthcare more accessible in remote areas. The diabetes diagnostics industry will see further growth as the prevalence of obesity rises. Through 2030, the global diabetes diagnostics market will be dominated by players from North America, Asia Pacific, and Europe.

Diabetes Management Software Market- The rising prevalence of type 1 and type 2 diabetes is one of the factors driving the growth of the diabetes management software industry. Diabetes patients are growing as a result of unhealthy lifestyles, poor diets, and rising stress and tensions. As a result, in recent years, the adoption of diabetes management software has increased, resulting in a favourable impact on the diabetes management software market. Another factor driving the growth of the diabetes management software market is technological advancements. One of the most important elements driving the remarkable development in the use of diabetes management software is the increasing number of younger diabetics.

OTC Analgesics Market- Over the last few years, there has been an increase in the use of off-label medications, which are inexpensive and unapproved but effective in treating ailments. Off-label medications such as tricyclic antidepressants, antihistamines, anticonvulsants, selective serotonin reuptake inhibitors, anti-anxiety medicines, and steroids are increasingly being used to treat pain sensations. Because of the widespread availability of over-the-counter analgesics, which are administered with approved medications as maintenance therapy, symptom management linked with pain has become convenient and straightforward. The market for over-the-counter analgesics has shown to have a lot of potential all over the world.

About Fact.MR

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Reach out to us with your goals, and well be an able research partner.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Read more here:
Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy - BioSpace

New research, released by a team based in Turkey, Qatar, and the United Kingdom, has indicated that a specialised eye exam can be used to identify long COVID.

Published in the British Journal of Ophthalmology, the research found that corneal confocal microscopy (CCM) a non-invasive eye test that conducts real-time imaging of corneal nerve fibres can also potentially be used to confirm suspected cases of long COVID by identifying specific nerve damage.

CCM is also used to identify other conditions, such as diabetic neuropathy, Parkinsons disease, multiple sclerosis, and dementia.

THE LARGER CONTEXT

Penned by researchers from Turkeys Necmettin Erbakan University, Weill Cornell Medicine-Qatar (WCM-Q), and the UKs University of Manchester, the study stated that CCM identifies corneal small nerve fibre loss and increased DCs [dendritic cells] in patients with long COVID, especially those with neurological symptoms.

As a result, CCM could be used to objectively identify patients with long COVID.

The paper added: Long COVID is characterised by a range of potentially debilitating symptoms which develop in at least 10% of people who have recovered from acute SARS-CoV-2 infection.

Symptoms of long COVID include headache, tingling and/or numbness, neuropathic pain, a loss or change in the senses of taste and smell, and so called brain fog.

WHY IT MATTERS

According to a statement by WCM-Q, nerve damage observed in the corneas using CCM can be reliably used as an indicator of nerve damage in other parts of the body.

CCMs value as a diagnostic tool is increased by a number of important factors: the test takes only a few minutes, is completely non-invasive, causes almost no discomfort for patients, utilises existing and widely available ophthalmic equipment, and can be done in the clinic.

ON THE RECORD

The predominance of neurologic symptoms in people with long COVID prompted us to investigate whether CCM could be used to objectively identify nerve damage in patients with the disease, said Rayaz Malik, professor of medicine and assistant dean for clinical investigations at WCM-Q. We are the first group in the world to report a very strong association between nerve damage observed using CCM and long COVID.

Although the majority of people had mild COVID, patients with more severe disease had evidence of greater corneal nerve damage, suggesting that the severity of nerve damage may be related to the severity of disease at presentation.

We believe CCM has the potential to serve as an extremely valuable tool to be used by physicians to help diagnose and assess the evolution of long COVID and to determine the severity in individual cases. The identification of underlying nerve damage also allows us to think about this condition as a neurodegenerative disease, which may be amenable to treatment.

Go here to read the rest:
CCM can identify nerve damage in patients with long COVID, new study finds - Mobihealth News